Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 4

Current treatment options in the management of chronic prostatitis

Authors Alain Jean Duclos, Chun-Te Lee, Daniel Arthur Shoskes

Published Date October 2007 Volume 2007:3(4) Pages 507—512

DOI

Published 4 October 2007

Alain Jean Duclos, Chun-Te Lee, Daniel Arthur Shoskes

Glickman Urological Institute, The Cleveland Clinic, 9500 Euclid Ave, Cleveland OH 44195, USA

Abstract: Chronic prostatitis is a disease with an unknown etiology that affects a large number of men. The optimal management for category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is unknown. The recent years have seen a significant increase in research efforts to understand, classify and treat CP/CPPS. Standard treatment usually consists of prolonged courses of antibiotics, even though well-designed clinical trials have failed to demonstrate their efficacy. Recent treatment strategies with some evidence of efficacy include: alpha-blockers, anti-inflammatory agents, hormonal manipulation, phytotherapy (quercetin, bee pollen), physiotherapy and chronic pain therapy. A stepwise, multimodal approach can be successful for the majority of patients who present with this difficult condition.

Keywords: prostatitis, chronic, treatment, management, CPPS

Download Article [PDF] 

Readers of this article also read:

Cryo-ablation improves anti-tumor immunity through recovering tumor educated dendritic cells in tumor-draining lymph nodes

He XZ, Wang QF, Han S, Wang HQ, Ye YY, Zhu ZY, Zhang SZ

Drug Design, Development and Therapy 2015, 9:1449-1458

Published Date: 10 March 2015

Spinal cord demyelination combined with hyperhomocysteinemia: a case report

Hao MM, Zhang Y, Hou SX, Chen YL, Shi M, Zhao G, Deng YC

Neuropsychiatric Disease and Treatment 2014, 10:2057-2059

Published Date: 3 November 2014

Obstructive jaundice caused by intraductal metastasis of lung adenocarcinoma

Ochi N, Goto D, Yamane H, Yamagishi T, Honda Y, Monobe Y, Kawamoto H, Takigawa N

OncoTargets and Therapy 2014, 7:1847-1850

Published Date: 7 October 2014

Social phobia in Parkinson’s disease: Prevalence and risk factors

Gultekin BK, Ozdilek B, Bestepe EE

Neuropsychiatric Disease and Treatment 2014, 10:829-834

Published Date: 21 May 2014

Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics

Cheng M, Chen H, Wang Y, Xu H, He B, Han J, Zhang Z

International Journal of Nanomedicine 2014, 9:695-710

Published Date: 24 January 2014

Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer

Sun W, Ai T, Gao Y, Zhang Y, Cui J, Song L

OncoTargets and Therapy 2013, 6:1315-1323

Published Date: 18 September 2013

A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles

Bachler G, von Goetz N, Hungerbühler K

International Journal of Nanomedicine 2013, 8:3365-3382

Published Date: 2 September 2013

Rare synchronous association of vestibular schwannoma and indolent insular oligodendroglioma in a patient without neurofibromatosis: controversial issue of timing for surgical treatment of asymptomatic low-grade gliomas

Iacoangeli M, Di Rienzo A, Colasanti R, Alvaro L, Nocchi N, Polonara G, Di Somma LG, Zizzi A, Scarpelli M, Scerrati M

OncoTargets and Therapy 2012, 5:357-361

Published Date: 19 November 2012

Decitabine in the treatment of myelodysplastic syndromes

Hussain I Saba

Therapeutics and Clinical Risk Management 2007, 3:807-817

Published Date: 22 November 2007